Stephen K. Doberstein, SVP & Chief Scientific Officer at NEKTAR THERAPEUTICS (NKTR), sold 6,620 shares at $42.39 ($281K) on 2019-02-19, disclosed to the SEC on 2019-02-21.
Seasonal sale ($281k) by SVP & Chief Scientific Officer — this insider has traded NKTR in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.39 | 3,310 | $140K | 50.0% |
| 2 | $42.39 | 3,310 | $140K | 50.0% |
| Total | $42.39 avg | 6,620 | $281K | 100% |
| Filing → |
| NKTR | SELL | 2019-05-17 | $217K | — | Filing → |
| NKTR | SELL | 2018-11-19 | $173K | — | Filing → |
| NKTR | SELL | 2018-05-18 | $573K | — | Filing → |